Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Description

Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015

Summary

“Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015” report is an essential source of information and analysis on the global insulin delivery devices market. The report identifies the key trends shaping and driving the dynamism in the global insulin delivery devices market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insulin delivery devices sector.

Scope

- Annualized global insulin delivery devices market revenues data from 2001 to 2008, forecast forward for 7 years to 2015. Updated company shares data for 2008.
- Key categories covered in this report are insulin pumps, insulin pens and insulin syringes
- Analysis and review of the key events and milestones that will impact the future of the global insulin delivery devices market. Each trend independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
- Insightful review of key industry drivers, restraints and challenges which are likely to impact the global insulin delivery devices market in the long run.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies. Key companies covered include Becton, Dickinson and Company, Medtronic, F. Hoffmann La Roche, Novo Nordisk, Sanofi Aventis, Eli Lilly, and Animas Corporation
- Comprehensive analysis of the most likely developments expected to bring a shift to the market positions of the leading manufacturers.
- The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global insulin delivery devices market.
- Identify key players best positioned to take advantage of the emerging market opportunities by developing insight on the prevalent and anticipated competitive landscape.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global insulin delivery devices market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Support your go/non-go dilemma by identifying the markets that are least competitive and present significant opportunities for innovation and growth.
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Table of Contents

1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Insulin Delivery Devices Pipeline Technology and Market Forecasts to 2015 8
2.1 Executive Summary 8
3 Insulin Delivery Devices Technology Landscape 10
3.1 Overview 10
3.2 History 11
3.3 Emerging Trends 11
3.3.1 Artificial Pancreas 11
3.3.2 MEMS Technology for Insulin Delivery 11
3.3.3 Transdermal Delivery and Insulin Patch 12
3.3.4 Inhaled Insulin 12
3.3.5 Oral Insulin 12
4 Global Insulin Delivery Devices Market Characterization 13
4.1 Market Overview 13
4.2 Insulin Delivery Devices Market Size 13
4.3 Insulin Delivery Devices Market Forecast and CAGR 14
4.4 Insulin Syringes Market Forecast and CAGR 18
4.5 Insulin Pens Market Forecast and CAGR 20
4.6 Insulin Pumps Market Forecast and CAGR 22
4.7 Market Dynamics 24
4.7.1 Market Drivers 24
4.7.1.1 Large Diabetic Population Worldwide Driving Insulin Delivery Devices Market 24
4.7.1.2 Increasing Ageing and Obese Population Contribution to Diabetes Epidemic 24
4.7.1.3 Technological Advancements Will Drive the Insulin Delivery Devices Market 24
4.7.2 Market Restraints 25
4.7.2.1 Low Diagnosis Rate 25
4.7.2.2 Low Patient Compliance 25
4.7.2.3 Reimbursement and Overall Cost Is a Restraint for Insulin Pens and Pumps 25
4.8 Insulin Delivery Devices Cross Country Analysis 26
4.9 Insulin Delivery Devices Cross Segment Analysis 28
4.10 Opportunity and Unmet Need 30
4.11 Key Takeaway 32
5 Insulin Delivery Devices Competitive Landscape 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 33
5.3 Insulin Delivery Devices Company Shares 36
5.3.1 Becton, Dickinson and Company 36
5.3.2 Medtronic 36
5.3.3 Novo Nordisk 37
5.3.4 Sanofi Aventis 37
5.3.5 Others 38
5.3.5.1 Insulet Corporation 38
5.3.5.2 NiliMEDIX 38
5.3.5.3 Medingo Ltd. 38
5.3.5.4 Debiotech S.A 39
5.3.5.5 Phluid Corporation 39
5.3.5.6 Ratio Inc. 39
5.3.5.7 Insuline Medical Ltd. 39
5.3.5.8 Aradigm Corporation 39
5.3.5.9 MannKind Corporation 39
5.3.5.10 Altea Therapeutics Corporation 39
5.4 Key Takeaway 40
6 Insulin Delivery Devices Pipeline Products 41
6.1 Overview 41
6.2 Strategic Pipeline Assessment 41
6.3 Insulin Delivery Devices – Clinical Pipeline by Mode of Insulin Delivery 44
6.4 Insulin Delivery Devices – Pipeline by Clinical Phase of Development 45
6.5 Global Insulin Delivery Devices Pipeline Product Summary 46
6.6 Global Insulin Pumps Pipeline Product Summary 47
6.7 Global Insulin Pens Pipeline Product Summary 48
6.8 Global Insulin Syringes Pipeline Product Summary 48
6.9 Global Insulin Patch Pipeline Product Summary 48
6.10 Global Inhaled Insulin Pipeline Product Summary 49
6.11 Insulin Delivery Devices – Promising Devices in Clinical Development 50
6.11.1 Closed-loop diabetes management system 50
6.11.1.1 Product Status 50
6.11.1.2 Product Description 50
6.11.2 Paradigm Veo System 51
6.11.2.1 Product Status 51
6.11.2.2 Product Description 51
6.11.3 AERx insulin Diabetes Management System 52
6.11.3.1 Product Status 52
6.11.3.2 Product Description 52
6.11.3.3 Clinical Trial One 53
6.11.3.4 Clinical Trial Two 54
6.11.3.5 Clinical Trial Three 55
6.12 Key Takeaway 56
7 Insulin Delivery Devices – Future Market Competition 57
7.1 Strategic Competitor Assessment 58
8 Reimbursement for Insulin Delivery Devices 59
9 Appendix 61
9.1 Market Definitions 61
9.1.1 Insulin Delivery 61
9.1.1.1 Insulin Pens 61
9.1.1.2 Insulin Pumps 62
9.1.1.3 Insulin Syringes 62
9.1.1.4 Traditional Insulin Pump Accessories 62
9.2 Abbreviations 62
9.3 Research Methodology 63
9.4 Secondary Research 64
9.5 Primary Research 64
9.6 Models 65
9.7 Forecasts 65
9.8 Expert Panels 65
9.9 GlobalData Consulting 66
9.10 Contact Us 66
9.11 Disclaimer 66

List of Tables

1.1 List of Tables
Table 1: Comparison of Insulin Delivery Devices 10
Table 2: Insulin Delivery Devices, Global, Revenue, 2000-2008 15
Table 3: Insulin Delivery Devices, Global, Revenue ($ m), 2008-2015 17
Table 4: Insulin Syringes, Global, Revenue ($ m), 2000-2008 18
Table 5: Insulin Syringes, Global, Revenue ($ m), 2008-2015 19
Table 6: Insulin Pens, Global, Revenue ($ m), 2000-2008 20
Table 7: Insulin Pens, Global, Revenue ($ m), 2008-2015 21
Table 8: Insulin Pumps, Global, Revenue ($ m), 2000-2008 22
Table 9: Insulin Pumps, Global, Revenue ($ m), 2008-2015 23
Table 10: Insulin Delivery Devices Cross Country Analysis of Revenue, 2000-2015 27
Table 11: Insulin Delivery Devices Cross Segment Analysis of Revenue, 2000-2015 28
Table 12: Sanofi Aventis Insulin Pen Product Portfolio 38
Table 13: Global Insulin Delivery Devices Pipeline Product Summary 46
Table 14: Global Insulin Pumps Pipeline Product Summary 47
Table 15: Global Insulin Pens Pipeline Product Summary 48
Table 16: Global Insulin Syringes Pipeline Product Summary 48
Table 17: Global Insulin Patch Pipeline Product Summary 48
Table 18: Global Inhaled Insulin Pipeline Product Summary 49
Table 19: Closed-loop diabetes management system, Product Status 50
Table 20: Closed-loop diabetes management system, Product Description 50
Table 21: Paradigm Veo System, Product Status 51
Table 22: Paradigm Veo System, Product Description 51
Table 23: AERx insulin Diabetes Management System, Product Status 52
Table 24: AERx insulin Diabetes Management System, Product Description 52
Table 25: AERx insulin Diabetes Management System - Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes 53
Table 26: AERx insulin Diabetes Management System - Inhaled Pre-Prandial Human Insulin With the AERx iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-Label, Multicenter, Randomized, Trial Followed by a 12 Week re-Randomized Extension to Investigate Safety and Efficacy 54
Table 27: AERx insulin Diabetes Management System - Inhaled Mealtime Insulin With the AERx iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomized, Parallel Trial (Followed by a Twelve-Week Re-Randomized Extension) To Investigate Safety and Efficacy 55

List of Figures

1.2 List of Figures
Figure 1: History of Insulin Delivery Devices 11
Figure 2: Insulin Delivery Devices, Global, Revenue ($ m) 2000-2008 14
Figure 3: Insulin Delivery Devices, Global, Revenue ($ m), 2008-2015 16
Figure 4: Insulin Syringes, Global, Revenue ($ m), 2000-2008 18
Figure 5: Insulin Syringes, Global, Revenue ($ m), 2008-2015 19
Figure 6: Insulin Pens, Global, Revenue ($ m), 2000-2008 20
Figure 7: Insulin Pens, Global, Revenue ($ m), 2008-2015 21
Figure 8: Insulin Pumps, Global, Revenue ($ m), 2000-2008 22
Figure 9: Insulin Pumps, Global, Revenue ($ m), 2008-2015 23
Figure 10: Insulin Delivery Devices Cross Country Analysis of Revenue, 2000-2015 26
Figure 11: Insulin Delivery Devices Cross Segment Analysis of Revenue, 2000-2015 28
Figure 12: Opportunity and Unmet Need 31
Figure 13: Strategic Competitive Assessment – Insulin Pumps 34
Figure 14: Strategic Competitive Assessment – Insulin Pens 35
Figure 15: Global Insulin Delivery Devices Market, Company Share (%), 2008 36
Figure 16: Technology Trends Analytic Framework 42
Figure 17: Technology Trends Analytic Framework - Descriptions 43
Figure 18: Insulin Delivery Devices – Clinical Pipeline by Mode of Insulin Delivery 44
Figure 19: Insulin Delivery Devices Pipeline by Clinical Phase of Development 45
Figure 20: Strategic Competitor Assessment 58
Figure 21: Reimbursement for Insulin Delivery Devices 59
Figure 22: Reimbursement Mix – Insulin Pens 60
Figure 23: GlobalData Methodology 63